coming paradigm shift, page-22

The main issue from a medical point of view is that although CVac may be beneficial in early ovarian cancer is identifying and treating these patients. Patients don't present with early ovarian cancer because it typically has no symptoms in the early stages. Generally symptoms are present once the cancer is already advanced and has spread.

Unlike cervical cancer there are currently no good screening tests for ovarian cancer. The closest we have is a blood test for Ca-125, however, low stage ovarian cancers do not elevate the levels while a variety of other conditions may falsly elevate the levels of Ca-125. So it is a very hard medically to pick up patients with early ovarian cancer.

For CVac to find widespread use in early ovarian cancer, or to quote the abstract from the article - vaccinating at the earliest possible stage of carcinogenesis - the medical field would first need to develop more specific screening tests for ovarian cancer (and this is an area of active research) and then demonstrate a benefit in clinical trials. Until this is achieved the use of CVac in EARLY ovarian cancer is a long way off in my opinion.